Relieves bronchospasm. ANDA 77839, held by Ritedose Corp. Albuterol Sulfate.
As of Nov 16, 2026, ANDA 77839 (Albuterol Sulfate), held by Ritedose Corp, was first approved by FDA on Dec 16, 2008, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Albuterol sulfate inhalation solution is indicated for the relief of bronchospasm in patients 2 years of age and older with reversible obstructive airway disease and acute attacks of bronchospasm.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 16, 2008 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Albuterol SulfateEQ 0.083% BASE · solution;inhalation | Albuterol Sulfate | Rx |
| Jan 28, 2013 | Supplement 13Labeling · Standard review | Approved | None posted |
| Dec 16, 2008 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters